Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Human B7-1 / CD80 Protein, Fc Tag, Avi Tag (Avitag™)(MALS verified), 25µg  

Recombinant Biotinylated Human B7-1 / CD80 Protein, Fc Tag, Avi Tag (Avitag™)(MALS verified), 25µg

Biotinylated Human B7-1 / CD80 Protein, expressed from human 293 cells (HEK293), Fc tag, Avi tag (Avitag™) (MALS verified)

Synonym
recombinant, human, biotinylated, protein, CD80, B7, B7-1, B7.1, BB1, CD28LG, CD28LG1, LAB7

More details

B71-H82F2-25

Availability: within 7 days

420,00 €

Background
B7-1 and B7-2, together with their receptors CD28 and CTLA­4, constitute one of the dominant co-stimulatory pathways that regulate T­ and B­cell responses. Although both CTLA­4 and CD28 can bind to the same ligands, CTLA­4 binds to B7­1 and B7­2 with a 20 ­ 100 fold higher affinity than CD28 and is involved in the down­regulation of the immune response. B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

Source
Recombinant Biotinylated Human B7-1, Fc,Avitag (B71-H82F2) is expressed from human 293 cells (HEK293). It contains AA Val 35 - Asn 242 (Accession # NP_005182.1).
Predicted N-terminus: Val 35

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus, followed by a Avi tag (Avitag™).
The protein has a calculated MW of 52.3 kDa. As a result of glycosylation, The protein migrates as 65-95 kDa under reducing (R) condition and 130-160 kDa under non-reducing (NR) condition on SDS-PAGE gel.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio
The biotin to protein ratio is 0.5-1 as determined by the HABA assay.

Endotoxin
Less than 1.0 EU per μg by the LAL method.
 
Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
 
Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Integrated analysis reveals distinct molecular, clinical, and immunological features of B7-H3 in acute myeloid leukemia"
Zhang, Jin, Xia et al
Cancer Med (2021)
(2) "Characterization and immunomodulatory activity of sulfated galactan from the red seaweed Gracilaria fisheri"
Khongthong, Theapparat, Roekngam et al
Int J Biol Macromol (2021) 189, 705-714
(3) "Spike protein of SARS-CoV-2 activates macrophages and contributes to induction of acute lung inflammation in male mice"
Cao, Tian, Nguyen et al
FASEB J (2021) 35 (9), e21801
Showing 1-3 of 5969 papers.
Please refer to product data sheet.
 
Limited Use License
The Biotin AviTag technology is covered by U.S. Pat. No: 5,874,239 and includes any and all materials, methods, kits and related derivatives claimed by this patent.
The purchase of the Acrosbiosystems’s Avitag™ proteins confers to the purchaser the limited right to use the Avitag™ technology for non-commercial, or research use, or for purposes of evaluating the Avitag™ technology.